The National Organization for Rare Disorders (NORD®) looks forward to working with Dr. Janet Woodcock as Acting Commissioner of the US Food and Drug Administration (FDA). Dr. Woodcock has consistently demonstrated her deep commitment to the rare disease patient community. Under her leadership, FDA has made important advances in regulatory science which have helped foster the much-needed development of hundreds of orphan drugs. The rare disease community also has benefited from Dr. Woodcock’s central role at the agency over the last year as treatments and vaccines for COVID-19 have become available. NORD is confident she will provide the leadership FDA needs now during these challenging times, and in the future, should President Biden nominate her to be permanent Commissioner.
Statement from NORD on Dr. Janet Woodcock, Acting Commissioner of the US Food and Drug Administration (FDA)
Categorized in -
